NAMSW vs NBP

NewAmsterdam Pharma Company N.V vs NovaBridge Biosciences — Valuation Comparison 2026

NAMSW

Pharmaceutical Preparations
NewAmsterdam Pharma Company N.V
Quality
2.2
out of 10
Value Trap
Price
$25.00
Last close
Models
8/13
Active
VS

NBP

Pharmaceutical Preparations
NovaBridge Biosciences
Quality
3.0
out of 10
Value Trap
12
SAFE
Price
$1.84
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType NAMSW Fair ValueNAMSW Upside NBP Fair ValueNBP Upside
Bayesian DCF Intrinsic $0.34 -81.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.60 -83.1% $1.39 -24.4%
Dynamic NAV Asset-Based $6.79 -68.0% $1.00 -45.6%
PWERM Option-Based $6.62 -68.8% $2.15 +16.8%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NAMSW vs NBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NAMSW vs NBP — Which Stock Is More Undervalued?

NBP scores higher with a 3.0/10 quality rating vs NAMSW's 2.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NewAmsterdam Pharma Company N.V (NAMSW) and NovaBridge Biosciences (NBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NAMSW currently trades at $25.00 with a QOC of 2.2/10, while NBP trades at $1.84 with a QOC of 3.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).